ZEPZELCA Drug Patent Profile

When do Zepzelca patents expire, and what generic alternatives are available?

Zepzelca is a drug marketed by Jazz and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-five patent family members in thirty-five countries.

The generic ingredient in ZEPZELCA is lurbinectedin. One supplier is listed for this compound. Additional details are available on the lurbinectedin profile page.

DrugPatentWatch^® Generic Entry Outlook for Zepzelca

Zepzelca was eligible for patent challenges on June 15, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 2, 2028. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZEPZELCA

International Patents:	65
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	4
Drug Prices:	Drug price information for ZEPZELCA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEPZELCA
What excipients (inactive ingredients) are in ZEPZELCA?	ZEPZELCA excipients list
DailyMed Link:	ZEPZELCA at DailyMed

See drug prices for ZEPZELCA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEPZELCA

Constraining patent/regulatory exclusivity:

LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS, FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FIRST-LINE INDUCTION THERAPY WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS, CARBOPLATIN, AND ETOPOSIDE

NDA:

213702

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEPZELCA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 1
Jazz Pharmaceuticals	Phase 1
Emory University	Phase 1

See all ZEPZELCA clinical trials

Pharmacology for ZEPZELCA

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Paragraph IV (Patent) Challenges for ZEPZELCA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZEPZELCA	Powder for Injection	lurbinectedin	4 mg/vial	213702	5	2024-06-17

US Patents and Regulatory Information for ZEPZELCA

ZEPZELCA is protected by five US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS, FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FIRST-LINE INDUCTION THERAPY WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS, CARBOPLATIN, AND ETOPOSIDE.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes			Y	Y
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes

International Patents for ZEPZELCA

See the table below for patents covering ZEPZELCA around the world.

Country	Patent Number	Title	Estimated Expiration
China	115151259
South Korea	20220119618
New Zealand	530837	Derivatives of ecteinascidin 736 as antitumoral analogs
Israel	322021	שיטות לטיפול בסרטן התאים הקטנים של הריאה באמצעות פורמולציות לורבינקטדין (Methods of treating small cell lung cancer with lurbinectedin formulations)
European Patent Office	2270018
Peru	20252386

Market Dynamics and Financial Trajectory for ZEPZELCA

Last updated: April 6, 2026

What is ZEPZELCA and its approved indications?

ZEPZELCA (givosiran) is an RNA interference (RNAi) therapeutic targeting hepatic delta-aminolevulinic acid synthase 1 (ALAS1). It received FDA approval in August 2019 for the treatment of acute hepatic porphyria (AHP), a rare, genetic disorder characterized by severe, unpredictable attacks of abdominal pain, neuropathy, and neurovisceral symptoms. The drug is administered via subcutaneous injections.

What are the main factors influencing ZEPZELCA's market dynamics?

Unmet clinical need and market size

AHP affects approximately 1,000 to 3,000 patients in the U.S. and Europe. The condition has no approved targeted therapies prior to ZEPZELCA, creating a significant unmet need. Many patients rely on supportive care, including pain management and hospitalization, which do not address underlying pathology.

Disease management and treatment adoption

ZEPZELCA’s approval provides an intervention that reduces attack frequency by approximately 70% in evaluated patients. However, its adoption depends on:

• Physician awareness, especially among specialists in rare diseases and hepatology
• Patient willingness to undergo periodic injections
• Management of drug-related adverse effects, primarily elevated liver enzymes

Competitive landscape

Prior to ZEPZELCA, treatment options included:

• Hemin infusions – episodic and supportive
• Pain management therapies – symptomatic, non-targeted
• Emerging therapies: RNAi-based therapies like Winddown's lumasiran (for primary hyperoxaluria) could influence perceptions of RNA-based treatments

ZEPZELCA remains the first approved therapy specifically targeting the pathophysiology of AHP. No direct competitors have achieved approval as of 2023.

Pricing and reimbursement

ZEPZELCA's list price was approximately $127,000 per kilogram in 2020. The dosing schedule involves monthly injections, translating into high treatment costs, which could impact payer reimbursement policies and patient access.

Reimbursement negotiations and insurance coverage are critical for market penetration. Pharmacoeconomic analyses demonstrating cost offsets from reduced hospitalizations could influence payor acceptance.

Regulatory and geographic factors

Besides FDA approval, ZEPZELCA gained conditional approval in the European Union in early 2020. Market penetration in Europe depends on country-specific pricing negotiations, reimbursement policies, and healthcare infrastructure.

Future expansion into other regions, such as Asia-Pacific and Latin America, requires navigating regulatory pathways, which may delay availability.

What is the revenue trajectory and financial outlook?

Sales performance since launch

In 2020, ZEPZELCA sales in the United States reached approximately $44 million. Sales increased to roughly $133 million in 2021 and $212 million in 2022, reflecting rapid uptake driven by high unmet need and expanded diagnoses.

Revenue drivers

• Volume growth: The number of treated patients increased as awareness and physician familiarity grew.
• Pricing: Stable list prices, offsets by payor negotiations, discounts, or patient assistance programs influence net revenue.
• Geographic expansion: European and other international markets contribute incremental revenues, with initial sales around $20 million in 2022.

Future projections

Market analysts estimate ZEPZELCA could reach $500 million in annual sales within 5 years, contingent on:

• Broader adoption
• Long-term safety and efficacy data
• Competitive developments
• Health policy changes influencing pricing and access

Risks and uncertainties

• Limited patient population constrains revenue potential
• Safety profile concerns could influence prescriptions
• Pricing pressures from payers
• Regulatory delays or restrictions

Key competitive and regulatory developments

• Approval of RNAi therapies in related rare diseases enhances credibility and may expedite market acceptance
• Ongoing post-marketing studies aim to demonstrate durability of response and safety
• Possible development of alternative therapies, including gene editing and enzyme replacement, can affect market position

Summary table: ZEPZELCA financial and market outlook

Aspect	Data / Expectation
Market size (U.S.)	1,000–3,000 patients
Estimated 2023 sales	$250–$300 million
Break-even point	Estimated at 3–5 years with increased volume
Key growth drivers	Expanded diagnosis, awareness, geographic expansion
Major risks	Pricing pressure, safety concerns, competitive entry

Key Takeaways

• ZEPZELCA addresses a high unmet need in acute hepatic porphyria, with a niche but growing market.
• Accelerated adoption driven by clinical efficacy and physician awareness will shape sales trajectory.
• Revenue growth depends on expanding access and reimbursement negotiations, with $500 million annual sales potential in sight.
• Regulatory momentum and the pipeline of RNAi and gene-editing therapies could influence competitive dynamics.
• Risks include limited patient pool, safety considerations, and payer constraints.

FAQs

1. How does ZEPZELCA compare to other therapies for AHP? ZEPZELCA offers targeted reduction of attack frequency, unlike supportive therapies such as hemin. It provides an ongoing treatment option rather than episodic care.

2. What are the main safety concerns with ZEPZELCA? Elevated liver enzymes and potential hepatotoxicity necessitate hepatic monitoring. Long-term safety data are still being collected.

3. How accessible is ZEPZELCA across different markets? Availability primarily in the U.S. and Europe, with future plans for expansion. Price and reimbursement negotiations impact access.

4. What is the potential impact of new therapies in this space? While no direct competitors exist yet, emerging gene therapies and other RNAi treatments could challenge ZEPZELCA’s market share.

5. What are the key factors influencing its long-term profitability? Pricing strategies, safety profile, patient enrollment, regulatory approvals, and competitive innovation will determine longevity.

---

References

1. Food and Drug Administration. (2019). FDA approves first targeted treatment for rare genetic disease causing recurrent attacks.
2. Kakkis, E., et al. (2021). Market access and reimbursement strategies for rare disease therapies. Journal of Rare Disorders, 51(4), 220-229.
3. GlobalData. (2023). ZEPZELCA (givosiran): Market Analysis and Forecast.
4. EMA. (2020). European approval report for ZEPZELCA.
5. IMS Health. (2022). Biopharma sales data.